Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.
Seckinger A, Buatois V, Moine V, Daubeuf B, Richard F, Chatel L, Viandier A, Bosson N, Rousset E, Masternak K, Salgado-Pires S, Batista C, Mougin C, Juan-Bégeot F, Poitevin Y, Hose D. Seckinger A, et al. Among authors: masternak k. Front Immunol. 2024 Apr 24;15:1378813. doi: 10.3389/fimmu.2024.1378813. eCollection 2024. Front Immunol. 2024. PMID: 38720892 Free PMC article.
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
Seckinger A, Majocchi S, Moine V, Nouveau L, Ngoc H, Daubeuf B, Ravn U, Pleche N, Calloud S, Broyer L, Cons L, Lesnier A, Chatel L, Papaioannou A, Salgado-Pires S, Krämer S, Gockel I, Lordick F, Masternak K, Poitevin Y, Magistrelli G, Malinge P, Shang L, Kallendrusch S, Strein K, Hose D. Seckinger A, et al. Among authors: masternak k. J Hematol Oncol. 2023 Dec 12;16(1):117. doi: 10.1186/s13045-023-01516-3. J Hematol Oncol. 2023. PMID: 38087365 Free PMC article.
Bioactive-Based Cosmeceuticals: An Update on Emerging Trends.
Goyal A, Sharma A, Kaur J, Kumari S, Garg M, Sindhu RK, Rahman MH, Akhtar MF, Tagde P, Najda A, Banach-Albińska B, Masternak K, Alanazi IS, Mohamed HRH, El-Kott AF, Shah M, Germoush MO, Al-Malky HS, Abukhuwayjah SH, Altyar AE, Bungau SG, Abdel-Daim MM. Goyal A, et al. Among authors: masternak k. Molecules. 2022 Jan 27;27(3):828. doi: 10.3390/molecules27030828. Molecules. 2022. PMID: 35164093 Free PMC article. Review.
Selective CD47 targeting with a bispecific antibody.
Ferlin W, Masternak K, Shang L. Ferlin W, et al. Among authors: masternak k. Cancer Immunol Immunother. 2021 Apr;70(4):1161-1162. doi: 10.1007/s00262-020-02812-4. Epub 2021 Jan 2. Cancer Immunol Immunother. 2021. PMID: 33388996 Free PMC article. No abstract available.
Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E, Chauchet X, Richard F, Barba L, Moine V, Chatel L, Broyer L, Pontini G, Bautzova T, Juan F, Calloud S, Bosson N, Charreton M, Masternak K, Buatois V, Shang L. Hatterer E, et al. Among authors: masternak k. MAbs. 2020 Jan-Dec;12(1):1739408. doi: 10.1080/19420862.2020.1739408. MAbs. 2020. PMID: 32191151 Free PMC article.
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.
Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG. Buatois V, et al. Among authors: masternak k. Mol Cancer Ther. 2018 Aug;17(8):1739-1751. doi: 10.1158/1535-7163.MCT-17-1095. Epub 2018 May 9. Mol Cancer Ther. 2018. PMID: 29743205 Free PMC article.
31 results